# Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever

> **NCT06684431** · PHASE1 · COMPLETED · sponsor: **Karolinska Institutet** · enrollment: 15 (actual)

## Conditions studied

- Crimean Congo Hemorrhagic Fever

## Interventions

- **BIOLOGICAL:** N-pVAX1

## Key facts

- **NCT ID:** NCT06684431
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-12
- **Primary completion:** 2026-03-17
- **Final completion:** 2026-03-17
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06684431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06684431, "Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06684431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*